Liquidia R&D Day Webcast presentation October 28, 2025 ©2025 LIQUIDIA CORPORATION ALL RIGHTS RESERVED Forward-looking statements This presentation includes, and our response to questions may include, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). All statements contained in this presentation other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and fina ...

股价表现 - United Therapeutics股价在最近交易日上涨3.5%至286.14美元 成交量显著高于正常水平 [1] - 过去四周该股累计下跌7.7% 此次上涨可能源于股价在连续下跌后的修复 [1][2] 产品研发动态 - Insmed进行的肺动脉高压(PAH)研究取得积极结果 该研究评估了公司Treprostinil(明星产品Tyvaso活性成分)的前药制剂 [2] - Insmed的制剂可实现每日一次给药 而Tyvaso需要每日多次给药 [2] 财务预期 - 公司预计季度每股收益6.87美元 同比增长17.4% 预期营收7.9642亿美元 同比增长11.4% [3] - 过去30天共识EPS预期上调0.7% 盈利预期修正趋势与股价走势存在强相关性 [4] 行业比较 - 同属医疗-制药行业的BioCryst Pharmaceuticals股价下跌2%至10.40美元 过去一个月涨幅7.7% [4] - BioCryst预期EPS为0.02美元 同比增幅133.3% 当前Zacks评级为买入(2级) [5]